Bruton’s tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma-Reference-Cited by-同舟云学术

Bruton’s tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma

Published:2018-07-16 Issue:47 Volume:37 Page:6180-6194
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Li Tianfeng,Deng Yi,Shi Yu,Tian Ruijun,Chen Yonglong,Zou Lin,Kazi Julhash U.^ORCID,Rönnstrand Lars^ORCID,Feng Bo,Chan Sun On^ORCID,Chan Wai Yee,Sun Jianmin,Zhao Hui

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/s41388-018-0397-7.pdf

Reference43 articles.

1. Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am. 2010;24:65–86.

2. Louis CU, Shohet JM. Neuroblastoma: molecular pathogenesis and therapy. Annu Rev Med. 2015;66:49–63.

3. Tabbo F, Barreca A, Piva R, Inghirami G, European TCLSG. ALK signaling and target therapy in anaplastic large cell lymphoma. Front Oncol. 2012;2:41.

4. Tan SL, Liao C, Lucas MC, Stevenson C, DeMartino JA. Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic perspectives. Pharmacol Ther. 2013;138:294–309.

5. Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer. 2013;13:397–411.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials;Molecules;2023-03-06

2. Newly synthesized 6-substituted piperazine/phenyl-9-cyclopentyl containing purine nucleobase analogs act as potent anticancer agents and induce apoptosis via inhibiting Src in hepatocellular carcinoma cells;RSC Medicinal Chemistry;2023

3. Inhibition of PI3 kinase isoform p110α suppresses neuroblastoma growth and induces the reduction of Anaplastic Lymphoma Kinase;Cell & Bioscience;2022-12-30

4. Recent development of BTK-based dual inhibitors in the treatment of cancers;European Journal of Medicinal Chemistry;2022-04

5. BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway;Blood;2021-12-09